G\u00fcn\u00fcm\u00fczde kolon kanseri, hem d\u00fcnya genelinde yayg\u0131nl\u0131\u011f\u0131 hem de \u00f6l\u00fcm oranlar\u0131 a\u00e7\u0131s\u0131ndan ciddi bir sa\u011fl\u0131k sorunu olmay\u0131 s\u00fcrd\u00fcr\u00fcyor. Kanser tan\u0131s\u0131 konuldu\u011fu anda hastal\u0131\u011f\u0131n evresi, hastan\u0131n genel sa\u011fl\u0131\u011f\u0131 ve tedaviye yan\u0131t verme potansiyeli, hastal\u0131\u011f\u0131n seyri ve sa\u011fkal\u0131m a\u00e7\u0131s\u0131ndan kritik \u00f6neme sahip. Ancak mevcut prognostik modeller, genellikle sadece patolojik evreleme ve demografik fakt\u00f6rler \u00fczerine kurulu oldu\u011fu i\u00e7in her hastan\u0131n bireysel riskini ve hastal\u0131k seyrini \u00f6ng\u00f6rmede s\u0131n\u0131rl\u0131 kalabiliyor. Son y\u0131llarda molek\u00fcler biyoloji ve ileri teknoloji ara\u00e7lar\u0131n\u0131n geli\u015fimi, bu s\u0131n\u0131rlar\u0131 a\u015fma ve kolon kanserinde daha hassas ve ki\u015fiselle\u015ftirilmi\u015f tahmin modelleri olu\u015fturma yolunda umut vadediyor.<\/p>\n
Bu ba\u011flamda, yak\u0131n zamanda BMC Cancer dergisinde yay\u0131mlanan \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir \u00e7al\u0131\u015fma, kolon kanseri hastalar\u0131n\u0131n tan\u0131 konulmadan y\u0131llar \u00f6nce al\u0131nan kan \u00f6rneklerinde bulunan plazma proteom profilinin, hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 anlamada yeni ufuklar a\u00e7abilece\u011fini ortaya koydu. UK Biobank adl\u0131 geni\u015f bir genetik ve sa\u011fl\u0131k veri taban\u0131ndan al\u0131nan yakla\u015f\u0131k sekiz y\u0131l \u00f6ncesine ait plazma \u00f6rnekleri kullan\u0131larak ger\u00e7ekle\u015ftirilen ara\u015ft\u0131rmada Olink proteomik teknolojisiyle bir\u00e7ok proteinin y\u00fcksek hassasiyetle \u00f6l\u00e7\u00fcm\u00fc yap\u0131ld\u0131. Bu sayede t\u00fcm\u00f6r geli\u015fmeden \u00e7ok \u00f6nce meydana gelen molek\u00fcler de\u011fi\u015fiklikler ve bunlar\u0131n hastalar\u0131n uzun vadeli prognozuna etkisi de\u011ferlendirildi.<\/p>\n
Olink teknolojisi, bir \u00e7e\u015fit y\u00fcksek kapasiteli proteom analiz platformu olarak \u00f6n plana \u00e7\u0131k\u0131yor. Bu platform sayesinde birden fazla proteinin tek seferde, h\u0131zl\u0131 ve g\u00fcvenilir bir bi\u00e7imde \u00f6l\u00e7\u00fclmesi m\u00fcmk\u00fcn hale geliyor. Uzun y\u0131llard\u0131r biyomarker ke\u015ffi alan\u0131nda kullan\u0131lan teknikler i\u00e7erisinde Olink, \u00f6zellikle kan\/plazma \u00f6rneklerinde az miktarda biyomateryalle ayr\u0131nt\u0131l\u0131 ve \u00e7ok hedefli analiz yap\u0131labilmesiyle dikkat \u00e7ekiyor. Ara\u015ft\u0131rmac\u0131lar, UK Biobank \u00fczerinden sa\u011flanan \u00f6rneklerde bunu kullanarak, tan\u0131 konulmadan \u00f6nceki proteomik de\u011fi\u015fimlerin kolon kanseri geli\u015fiminde ve seyirinde ne denli belirleyici olabilece\u011fini g\u00f6sterdi.<\/p>\n
\u00c7al\u0131\u015fmada ortaya \u00e7\u0131kan en \u00f6nemli bulgulardan biri, kolon kanseri geli\u015fimi s\u00fcrecinde erken ve ge\u00e7 d\u00f6nemler i\u00e7in iki farkl\u0131 proteomik imzan\u0131n varl\u0131\u011f\u0131 oldu. Erken evre kolon kanseri vakalar\u0131nda belirginle\u015fen 10 proteinlik panelde, ekstrasel\u00fcler matrisin yeniden \u015fekillendirilmesi ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ka\u00e7\u0131\u015f mekanizmalar\u0131 \u00f6n plana \u00e7\u0131kt\u0131. Bu da daha kansere d\u00f6n\u00fc\u015fmeden \u00f6nce doku yap\u0131s\u0131nda ve ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6zetiminde \u00f6nemli bozulmalar\u0131n ya\u015fand\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Kanser h\u00fccrelerinin geli\u015fimi \u00f6ncesindeki bu molek\u00fcler de\u011fi\u015fimler, t\u00fcm\u00f6r\u00fcn agresifli\u011fi ve hastan\u0131n hayatta kalma s\u00fcresini etkileyecek nitelikte.<\/p>\n
\u00d6zellikle erken d\u00f6nemde ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin do\u011fal savunma mekanizmalar\u0131n\u0131n bozulmas\u0131, kanserin olu\u015fum ve ilerleyi\u015finde kritik bir fakt\u00f6r olarak de\u011ferlendiriliyor. Ara\u015ft\u0131rmada, ba\u011f\u0131\u015f\u0131kl\u0131k aktivasyon yolaklar\u0131ndaki d\u00fczensizliklerin, hastalar\u0131n ilerleyen s\u00fcre\u00e7te daha k\u00f6t\u00fc hayatta kalma olas\u0131l\u0131\u011f\u0131yla yak\u0131ndan ili\u015fkili oldu\u011fu saptand\u0131. Bu bulgu, kanserle sava\u015fta ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin rol\u00fcn\u00fc bir kez daha do\u011frularken, erken d\u00f6nemde ba\u011f\u0131\u015f\u0131kl\u0131kla ilgili belirte\u00e7lerin prognoz belirlemede kullan\u0131labilece\u011fini ortaya koydu.<\/p>\n
Ge\u00e7 evre kolon kanserinde g\u00f6zlemlenen 8 proteinlik farkl\u0131 bir profil ise h\u00fccre adezyonu, anjiyogenez (yeni damar olu\u015fumu) ve pro-inflamatuar (iltihap yarat\u0131c\u0131) yan\u0131tlarla ili\u015fkilendirildi. Kanser geli\u015fti\u011finde, t\u00fcm\u00f6r h\u00fccreleri \u00e7evre dokulara yap\u0131\u015fma, etraf\u0131ndaki damarlar\u0131 \u00e7o\u011faltarak beslenme sa\u011flama ve iltihabi ortam yaratma yetene\u011fi kazan\u0131r. \u0130\u015fte bu mekanizmalar, hastal\u0131\u011f\u0131n agresifle\u015fmesini tetikleyip tedaviye kar\u015f\u0131 diren\u00e7 geli\u015fme riskini art\u0131rabilir. Erken fark edilip hedeflenebilirlerse, hastalar\u0131n ya\u015fam beklentisinin uzat\u0131lmas\u0131 a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck f\u0131rsat sunar.<\/p>\n
Ara\u015ft\u0131rman\u0131n temel \u00e7\u0131kt\u0131lar\u0131 aras\u0131nda, pre-diagnostik yani kanser tan\u0131s\u0131ndan y\u0131llar \u00f6nceki protein profillerinin hastal\u0131k geli\u015fiminde biyolojik olarak anlaml\u0131 de\u011fi\u015fiklikler g\u00f6sterdi\u011fi, bunlar\u0131n ayn\u0131 zamanda tan\u0131 sonras\u0131 sa\u011fkal\u0131m\u0131 anlaml\u0131 \u015fekilde etkiledi\u011fi yer al\u0131yor. Bu veriler, kanser te\u015fhisinden \u00f6nceki s\u00fcre\u00e7te bile hastal\u0131\u011f\u0131n molek\u00fcler bir ayak izinin var oldu\u011funu, bu ayak izlerinin hastal\u0131\u011f\u0131n seyrini ve tedavi ba\u015far\u0131s\u0131n\u0131 tahmin etmek i\u00e7in kullan\u0131labilece\u011fini destekliyor.<\/p>\n
Bu t\u00fcr proteomik \u00e7al\u0131\u015fmalar \u00f6zellikle kolon kanserinde risk s\u0131n\u0131fland\u0131rmas\u0131nda devrim yaratabilir. Yaln\u0131zca evreleme ve klinik bulgulara dayanan tahmin modelleri yerine, bireysel molek\u00fcler farkl\u0131l\u0131klar\u0131 dikkate alan, ki\u015fiye \u00f6zel y\u00f6ntemler geli\u015ftirilebilir. B\u00f6ylece y\u00fcksek risk ta\u015f\u0131yan hastalar daha erken d\u00f6nemde tespit edilerek agresif tedavi veya daha s\u0131k takip programlar\u0131na al\u0131nabilir. \u00d6te yandan, d\u00fc\u015f\u00fck riskli hastalar\u0131n gereksiz y\u00fcksek yan etkili tedavilerden uzak tutulmas\u0131 da m\u00fcmk\u00fcn hale gelecek.<\/p>\n
UK Biobank \u00e7al\u0131\u015fmas\u0131n\u0131n b\u00fcy\u00fck \u00f6l\u00e7ekli veri taban\u0131 kullan\u0131larak yap\u0131lmas\u0131, bulgular\u0131n g\u00fcvenilirli\u011fini art\u0131r\u0131yor. \u00c7al\u0131\u015fma, farkl\u0131 ya\u015f, cinsiyet ve etnik k\u00f6kenlerden geni\u015f kat\u0131l\u0131mc\u0131 veri setiyle proteomik analiz yap\u0131ld\u0131\u011f\u0131nda, sonu\u00e7lar\u0131n genel pop\u00fclasyona genellenebilme g\u00fcc\u00fcne sahip oldu\u011funu g\u00f6steriyor. Bu da klinik uygulamalara ge\u00e7i\u015fte \u00f6nemli bir dayanak sa\u011fl\u0131yor.<\/p>\n
Sonu\u00e7 olarak, bu ara\u015ft\u0131rma, kanser \u00f6ncesi d\u00f6nemde organizmadaki proteomik de\u011fi\u015fimlerin sadece hastal\u0131\u011f\u0131n geli\u015fim mekanizmalar\u0131n\u0131 ayd\u0131nlatmakla kalmad\u0131\u011f\u0131n\u0131, ayn\u0131 zamanda hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 da \u00f6ng\u00f6rmede g\u00fc\u00e7l\u00fc biyobelirte\u00e7ler sundu\u011funu ispatl\u0131yor. Bu yeni nesil prognostik yakla\u015f\u0131m, kolon kanseri tedavisinde ki\u015fiselle\u015ftirilmi\u015f t\u0131p uygulamalar\u0131n\u0131 destekleyerek \u00f6l\u00fcm oranlar\u0131n\u0131 d\u00fc\u015f\u00fcrme potansiyeline sahip. Klinik pratikte ise plazma proteom profili belirleme testlerinin gelecekte tan\u0131 ve takiplerde rutin kullan\u0131m\u0131 m\u00fcmk\u00fcn olabilir.<\/p>\n
Kesinlikle, bu \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 \u00e7al\u0131\u015fma kolon kanseri alan\u0131nda proteomik teknolojilerin yeri ve \u00f6nemi konusunda yeni standartlar belirliyor. Olink platformunun sundu\u011fu y\u00fcksek do\u011fruluklu, \u00e7oklu protein \u00f6l\u00e7\u00fcm imkan\u0131, yap\u0131lan analizlerin g\u00fcc\u00fcn\u00fc art\u0131r\u0131yor ve erken d\u00f6nemde tan\u0131 koyma s\u00fcrecini h\u0131zland\u0131r\u0131yor. Ara\u015ft\u0131rma ayn\u0131 zamanda kanser biyolojisi ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ile olan karma\u015f\u0131k ili\u015fkilerin \u00e7\u00f6z\u00fcm\u00fcne \u0131\u015f\u0131k tutarak multidisipliner kanser yakla\u015f\u0131mlar\u0131n\u0131n geli\u015fimine katk\u0131 sa\u011fl\u0131yor.<\/p>\n
Bu bulgular \u0131\u015f\u0131\u011f\u0131nda, gelecekte yap\u0131lacak \u00e7al\u0131\u015fmalarla kolon kanserinin erken tan\u0131 ve prognozunun iyile\u015ftirilmesi y\u00f6n\u00fcnde yeni biyobelirte\u00e7lerin klinik onay almas\u0131 ve klinik rehberlere entegre edilmesi bekleniyor. Ayr\u0131ca imm\u00fcnoterapiler gibi ba\u011f\u0131\u015f\u0131kl\u0131k sistemini hedef alan tedavilerin erken evre hastalarda ba\u015far\u0131l\u0131 olabilmesi i\u00e7in plazma proteom yakla\u015f\u0131m\u0131n\u0131n bir yol g\u00f6sterici olabilece\u011fi d\u00fc\u015f\u00fcn\u00fcl\u00fcyor. B\u00f6ylece kanser y\u00f6netiminde t\u00fcm\u00f6r \u00f6ncesi evre ile hastal\u0131k sonras\u0131 ba\u015far\u0131 aras\u0131ndaki ba\u011flant\u0131lar somut verilerle desteklenmi\u015f olacak.<\/p>\n
Uzun vadeli projeksiyonlarla de\u011ferlendirildi\u011finde, pre-diagnostik plazma proteom profilinin sa\u011fkal\u0131m tahmininde kullan\u0131lmas\u0131 hem hasta ya\u015fam kalitesini art\u0131racak hem de sa\u011fl\u0131k sistemlerine ekonomik katk\u0131 sa\u011flayacak. Erken te\u015fhisle tedavinin m\u00fcmk\u00fcn olan en etkin a\u015famada ba\u015flamas\u0131, gereksiz ila\u00e7 kullan\u0131m\u0131 ve komplikasyonlar\u0131n azalt\u0131lmas\u0131 sa\u011flanabilir. Dolay\u0131s\u0131yla b\u00f6yle yenilik\u00e7i ara\u015ft\u0131rmalar hem bilim d\u00fcnyas\u0131nda hem de klinik pratikte fevkalade \u00f6nem ta\u015f\u0131yor.<\/p>\n
—<\/p>\n
**Ara\u015ft\u0131rma Konusu**: Pre-diagnostik plazma proteom profillerinin kolon kanseri hastalar\u0131n\u0131n sa\u011fkal\u0131m\u0131 \u00fczerindeki etkileri <\/p>\n
**Makale Ba\u015fl\u0131\u011f\u0131**: (Belirtilmemi\u015f) <\/p>\n
**Haberin Yay\u0131n Tarihi**: (Belirtilmemi\u015f) <\/p>\n
**Web References**: (Belirtilmemi\u015f) <\/p>\n
**Doi Referans**: (Belirtilmemi\u015f) <\/p>\n
**Resim Credits**: (Belirtilmemi\u015f) <\/p>\n
**Anahtar Kelimeler**: kolon kanseri, plazma proteom, Olink proteomik teknolojisi, sa\u011fkal\u0131m, biyobelirte\u00e7, UK Biobank, erken tan\u0131, imm\u00fcnoterapi, prognoz, ki\u015fiselle\u015ftirilmi\u015f t\u0131p<\/p>\n","protected":false},"excerpt":{"rendered":"
G\u00fcn\u00fcm\u00fczde kolon kanseri, hem d\u00fcnya genelinde yayg\u0131nl\u0131\u011f\u0131 hem de \u00f6l\u00fcm oranlar\u0131 a\u00e7\u0131s\u0131ndan ciddi bir sa\u011fl\u0131k sorunu olmay\u0131 s\u00fcrd\u00fcr\u00fcyor. Kanser tan\u0131s\u0131 konuldu\u011fu anda hastal\u0131\u011f\u0131n evresi, hastan\u0131n genel sa\u011fl\u0131\u011f\u0131 ve tedaviye yan\u0131t verme potansiyeli, hastal\u0131\u011f\u0131n seyri ve sa\u011fkal\u0131m a\u00e7\u0131s\u0131ndan kritik \u00f6neme sahip. Ancak mevcut prognostik modeller, genellikle sadece patolojik evreleme ve demografik fakt\u00f6rler \u00fczerine kurulu oldu\u011fu i\u00e7in…<\/p>\n","protected":false},"author":1,"featured_media":3414,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[2090,2087,2088,2089,2091],"tmauthors":[],"class_list":{"0":"post-3413","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-kolon-kanseri-erken-tani-ve-molekuler-biyoloji","9":"tag-kolon-kanseri-sagkaliminda-plazma-proteinleri","10":"tag-kolon-kanserinde-proteomik-biyobelirtecler","11":"tag-olink-proteomik-teknolojisi-ile-kanser-tahmini","12":"tag-uk-biobank-veri-tabaninda-kanser-arastirmalari"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Kolon-Kanseri-Sagkaliminda-Plazma-Proteinleri-1745264695.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3413"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3413\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3414"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3413"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}